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Background: The purpose of this study was to investigate the savings accrued using 
bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, 
taking only public costs into account, in France, Germany, Italy, and Spain.
Methods: Societal costs were estimated by collecting and analyzing labor costs, carer costs, 
sickness benefits, disability benefits, and home care benefits. Cost inputs were derived from 
publicly available databases or from the published literature. Expert opinion was only used if 
no other source was available. Efficacy data from two randomized clinical trials were used. The 
time horizon in the health economic model was lifetime. Efficacy and costs were discounted 
by 3.5%. All main model parameters were tested in deterministic and probabilistic sensitivity 
analyses.
Results: Mean incremental savings to society per patient ranged from €2277 in Italy to €4461 in 
Germany. The results were most sensitive to the change in proportion of patients working full-
time and the proportion of patients who were able to return to work.
Conclusion: This analysis shows that bevacizumab-based treatment in non-small-cell lung 
cancer is associated with more savings to society compared to standard chemotherapy in terms 
of increased productivity and decreased social benefits paid to patients who are able to work in 
France, Germany, Italy, and Spain.
Keywords: non-small-cell lung cancer, bevacizumab, chemotherapy, economic model, France, 
Germany, Italy, Spain
Introduction
There are about 200,000 new cases of lung cancer and 140,000 lung cancer deaths 
each year in the European Union.1 Patients with lung cancer have a poor prognosis. 
The disease accounts for approximately 20% of all cancer-related deaths in Europe, 
and accounts for more deaths than any other malignancy.2 The majority of lung can-
cer cases are diagnosed when the disease is at an advanced stage.3 The age-adjusted 
5-year survival rate for lung cancer is only around 10%.1 Non-small-cell lung cancer 
(NSCLC) accounts for around 80% of lung cancer cases.3
Patients with advanced lung cancer experience a high symptom burden.4–12 The 
significant burden on lung cancer patients is due to the large number of symptoms 
experienced and their severity, which increase as the disease progresses, and health-
related quality of life decreases accordingly.13 In addition to improving overall sur-
vival of advanced NSCLC patients, extending progression-free survival is a clinically 
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meaningful treatment goal for patients. Prolonging the time 
before symptoms worsen (disease progression) can delay the 
negative physical and emotional consequences associated 
with disease progression.
Bevacizumab is a monoclonal antibody against vascular 
endothelial growth factor and indicated for first-line treatment 
of unresectable, locally advanced, recurrent, or metastatic 
non-squamous NSCLC in combination with platinum-based 
chemotherapy in Europe.14 It has been shown to delay tumor 
progression significantly compared with standard platinum 
chemotherapy alone (Table 1).15,16 The efficacy of the various 
chemotherapies available has been shown to be similar.17,18 It 
has been reported that the efficacy of bevacizumab is gener-
ally consistent across chemotherapies, including carboplatin 
and cisplatin doublets.19
Research has demonstrated that improvements in health 
care have considerable value to society.20 The value is cre-
ated by investments in medical research and through the 
experiences using these technologies in clinical practice. 
Increasingly, questions are being asked about the value of 
new health technologies in respect to their costs. Although 
benefits are commonly considered in their widest possible 
sense; costs in economic evaluations are typically limited to 
the “payer” perspective.21,22 Some health technology assess-
ment and reimbursement agencies recommend considering 
the societal perspective.23 The societal perspective is defined 
as incorporating all costs and benefits, no matter who pays the 
costs and who receives the benefits.24 It has been argued that 
abandoning the societal perspective may lead to suboptimal 
decisions about allocation of resources.25 In this analysis, 
the societal perspective is defined as public health service 
and government.
Governments face high costs related to the treatment of 
lung cancer. Treatment of advanced lung cancer is associated 
with frequent hospital visits, surgery, radiation therapy, che-
motherapy, and targeted therapies. There are further losses 
arising from lost productivity due to sick leave, disability, 
and premature deaths linked to lung cancer. Patients with 
advanced NSCLC who can no longer work do not pay into 
social contribution schemes like health insurance funds, pen-
sion funds, or nursing care funds. Depending on the country, 
these payments will be made on behalf of the patient by the 
health insurance fund or out of tax funds. The productivity 
losses double when an employed family member becomes a 
carer for the patient with lung cancer. Additionally, patients 
who are no longer able to look after themselves will require 
formal care.
An observational cost-of-illness study, ie, ALCEA 
(Advanced Lung Cancer Economic Assessment), reports on 
considerable societal burden associated with the disease in 
patients with advanced NSCLC. A high level of health care 
resource utilization and a significant productivity loss were 
observed.26 Another study found that bevacizumab-based 
treatment can result in substantial cost savings in patients 
with advanced NSCLC who are progression-free.27 The aim 
of this study was to explore the incremental societal savings 
attributable to bevacizumab-based treatment compared with 
chemotherapy in France, Germany, Italy, and Spain.
Materials and methods
This study estimates the potential savings from the societal per-
spective resulting from reduced productivity losses in patients 
with advanced NSCLC in Germany, France, Italy and Spain.
A health economic model was developed to assess 
the societal savings associated with bevacizumab-based 
treatment when compared with chemotherapy. A Markov 
model was selected because it allows assessment of patient 
transition between different health states separately in both 
treatment arms. Patient level data from two randomized, 
controlled, double-blind Phase III trials of first-line therapy 
for advanced NSCLC were used to derive Markov model 
cycle-specific numbers of progression-free patients as well 
Table 1 Efficacy of randomized clinical trials
Description Chemotherapy Bevacizumab-based therapy
BO17704 Median time in progression-free survival (months) 6.1 6.7
95% confidence interval (months) 5.6–6.4 6.3–6.9
Hazard ratio 0.75
95% confidence interval 0.62–0.91
P value 0.0026
E4599 Median time in progression-free survival (months) 4.8 6.4
95% confidence interval (months) 4.40–5.39 6.11–6.87
Hazard ratio 0.65
95% confidence interval 0.56–0.76
P value ,0.0001
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as those patients whose disease progressed, who died, or 
who were censored.15,16,28 These data were fitted into Weibull 
distributions that were used to estimate the numbers of 
patients in each health state for the duration of the model. 
Health outcomes as well as associated costs were modeled in 
monthly cycles. The analysis time horizon was lifetime. The 
model has two states, ie, progression-free survival and disease 
progression or death. The progression-free survival state is 
divided into proportions of patients who can work after induc-
tion therapy and those who cannot do so. Each patient has a 
probability of having an informal carer, a formal carer, or not 
having a carer. Patients were given bevacizumab + standard 
chemotherapy or only standard chemotherapy. The chemo-
therapy was either cisplatin-gemcitabine or carboplatin-
paclitaxel. More details of the studies and treatment regimes 
have been described elsewhere.15,16,28 Clinical outcomes and 
costs were discounted at a rate of 3.5%.
All patients were assumed to be off work during the treat-
ment induction phase, when bevacizumab + chemotherapy 
or chemotherapy is administered for six cycles. Each treat-
ment cycle lasts 21 days for both therapies. The proportion 
of patients assumed to return to work after initial induction 
therapy was 32% for the bevacizumab-based treatment arm 
and 19% for the chemotherapy arm.29
Incident lung cancer patients in the working age popula-
tion were estimated from the Globocan database.2 The work-
ing age was defined as 15–55 years at the time of diagnosis. 
A normal distribution was assumed around the mean age to 
derive the cohort of patients who would be aged 55 years 
or under at diagnosis. Of these patients, clinical experts 
estimated that 36% were patients with advanced and/or 
metastatic NSCLC. The proportion of patients treated with 
various therapies was assumed to be equally split, eg, 25% 
each treated with bevacizumab + cisplatin-gemcitabine, 
bevacizumab + carboplatin-paclitaxel, cisplatin-gemcitabine, 
or carboplatin-paclitaxel.
Only patients who were employed prior to their diag-
nosis are considered in the study. The employment rates 
for France, Germany, Italy, and Spain are 64%, 71%, 
57%, and 59%, respectively.30 The proportions of patients 
assumed to be working full-time and part-time are shown 
in Table 2. These proportions were applied to both patients 
and informal carers. For simplicity, it was assumed that 
patients who worked full-time prior to their diagnosis would 
return to work full-time. The same assumption was made 
for part-time workers, ie, if they were part-time workers 
they returned to work part-time. The informal carer’s return 
to work was not dependent on their working status prior to 
diagnosis, but on whether the patient returned to work, and 
whether it was full-time or part-time. Thirteen percent of the 
patients were assumed to have informal carers.29
The patients who were estimated to return to work con-
tinued to work until disease progression or death, whichever 
occurred first. Only patients who were aged 55 years or under 
at the time of diagnosis were assumed to return to work. This 
estimate is based on expert opinion because no published 
evidence was identified.
The labor costs applied are shown in Table 2. The cost of 
sick leave and a possible disability pension were also taken 
into consideration. The details of the figures included are 
shown in Table 2. Informal carers were assumed to be on 
unpaid leave during the time that they were unable to work. 
No long-term benefits were considered in this study due to the 
complexity of including them. No home care benefits were 
assumed for Italy, because there was no home care benefit 
scheme in place during the study period.
Results
Our analysis shows that gains in productivity and associ-
ated reductions in societal expenditure are higher in the 
bevacizumab treatment arm (€5216, €6739, €3455, and 
€4046 per person in France, Germany, Italy, and Spain, 
respectively) than in the chemotherapy arm (€1774, €2278, 
€1178, and €1377, respectively). These societal gains are 
due to the time spent in progression-free survival by patients 
who were estimated to be able to return to work in each 
treatment arm. A comparison of the two treatments arms is 
shown in Figure 1.
Table 2 Model input data
Description France Germany Italy Spain
Employment rate 64.00% 71.10% 56.90% 58.60%
Employment at diagnosis (full-time) 87.72% 78.98% 84.61% 88.73%
Employment at diagnosis (part-time) 12.28% 21.02% 15.39% 11.27%
Labor cost (inflated) (€) 2798 3449 2215 2031
Sick leave benefit (amount, €) 1399 2414 1475 1523
Sick leave benefit (duration) 360 days 78 weeks 160 days 12 months
Disability pension (€) 738 684 680 936
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Most of the societal savings were accrued from reduced 
losses in labor costs. These savings represented 55%, 50%, 
64%, and 52% of all savings in France, Germany, Italy, and 
Spain, respectively. The rest of the societal savings were due 
to not having to file a claim sickness benefit, disability benefit, 
or home care benefit, and having reduced formal care costs. 
Additionally, if the patient had an informal carer, savings 
were increased because the carer was able to return to work. 
The breakdown of these savings can be seen in Figure 1.
To assess for uncertainty in the model structure and 
inputs, two types of sensitivity analysis techniques were used, 
ie, one-way and probabilistic. In one-way sensitivity analysis, 
the varied inputs were discounting rate (0% and 5%), time 
horizon (one year and 3 years), labor cost (±10%), propor-
tion of patients in full-time employment (of those who are 
employed) prior to diagnosis (0% and 100%), and proportion 
able to return to work (±10%). The results of the one-way 
sensitivity analyses are shown in Figure 2.
Probabilistic sensitivity analyses are often used to assess 
how uncertainty in model outputs can be apportioned to 
imperfect knowledge of the parameter input values. In 
our probabilistic sensitivity analysis, we used a cohort 
simulation technique to assess for parameter uncertainty. 
Cohort simulation is often used to test the robustness 
of the results of random variation in the values of the 
key parameters. The number of iterations run was 1000. 
Table 3 shows the results.
Discussion
For most patients, a diagnosis with advanced cancer is a 
terminal prognosis. The impact of advanced NSCLC extends 
beyond the individual, affecting both the emotional and 
financial well-being of patients and their families.
There are only a few studies published on the cost of 
illness in lung cancer, especially ones taking a societal 
perspective. Country cancer registries have been used to 
assess the overall morbidity from lung cancer.31,32 A study 
by Stanisic et al assessed the economic burden of metastatic 
NSCLC from a societal perspective,27 and found that the 
mean cost savings after one year were €21,667, €21,171, 
€17,578, and €12,401 in France, Germany, Italy, and Spain, 
respectively. The study results suggest that there are reduced 
productivity losses due to improved progression-free survival 
in patients treated with bevacizumab-based therapy compared 
with patients treated with chemotherapy alone. Another study 
found that the productivity losses associated with advanced 
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Figure 1 Comparison of Bevacizumab plus chemotherapy treatment and chemotherapy treatment savings (5 year cumulative savings).
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lung cancer were around €11,390,000 in Italy, making the 
average loss per patient approximately €60,263.26 The study 
by Perrone et al is a cost-of-illness study in Italy, assessing 
the direct and indirect costs associated with patients having 
lung cancer in Italy. Although these studies are not directly 
comparable with our analysis, our findings are in line with 
these studies. The previous work by Stanisic et al only took 
labor costs into consideration, whereas this analysis has taken 
a wider perspective by including productivity losses associ-
ated with informal carers, cost of formal carers, sick leave 
remuneration, disability pension, and home care benefits.27 
The outcomes from the Phase III trials used in our analysis 
are consistent with outcomes from the Phase IV trial.19
Our approach only took into account public expenditure, 
but excluded any similar private expenditure. For example, 
in Germany, the employer pays part of the sick leave remu-
neration, and after that it is paid by health insurance. The 
remuneration paid by the employer has not been included in 
our analysis. Including this expenditure would have increased 
the societal savings from bevacizumab-based therapy. Taking 
a wider societal perspective would have enabled inclusion 
of all changes in resources as measured by changes in ser-
vice production, changes in resources used by patients and 
their carers, and changes in the gross domestic product,33 
but would have resulted in a less conservative estimate of 
societal savings.
A real-life study was used to assess the proportion of 
patients who return to work after induction therapy.34 The 
study reported that 32% of bevacizumab-based and 19% 
of chemotherapy patients returned to work. Other studies 
in various countries report that the proportion of NSCLC 
patients returning to work was between 13% and 40%.29,35–38 
Hence, the real-life study results can be considered to be in 
line with previous findings.
Standard average OECD tax and contribution rates have 
been used in this study, and the average income has been 
used from the same source. However, this average income 
is available for single households only. There are reasons 
why this average might be considered an overestimation or 
underestimation. There is an inverse association between the 
highest level of education and lung cancer.39,40 On the other 
hand, patients with lung cancer tend to be older and there is a 
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Figure 2 One-way sensitivity analyses: impact of one parameter changing at the time.
Table 3 Probabilistic sensitivity analysis results
Description France Germany Italy Spain
Societal savings, bevacizumab-based treatment (±SD) 5216 ± 691 6702 ± 948 3429 ± 475 4060 ± 586
Societal savings, chemotherapy (±SD) 1770 ± 260 2272 ± 348 1173 ± 164 1380 ± 198
Incremental savings 3446 4431 2256 2680
Abbreviation: SD, standard deviation.
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higher proportion of males than in the general population, and 
hence they have a higher income than the general population. 
Rather than trying to adjust for these variables, we opted to 
use simply the average income to maintain transparency in 
our analysis.
As with any analysis, some assumptions had to be made 
due to no published data being available. In this analysis, only 
patients who were employed prior to their diagnosis were 
considered. It was also assumed that patients who worked 
full-time prior to their diagnosis would return to work 
full-time. The same assumption was made for part-time 
workers, ie, if they were part-time workers they returned to 
work part-time. These assumptions applied equally to the 
bevacizumab-based treatment arm and chemotherapy arm. 
Nevertheless, they could overestimate the savings.
Deterministic sensitivity analyses showed that changes 
in time horizon had very little impact on overall societal 
savings. Full-time employment and the proportion able to 
return to work seemed to have the most impact on savings 
in all other countries, except France. In France, the labor 
costs represented the most influential impact, followed by 
the proportion working full-time. The results of the proba-
bilistic sensitivity analysis are in line with the deterministic 
findings.
Currently, there are not many studies assessing savings 
related to treatments in advanced NSCLC from the societal 
perspective. This study has adopted the societal perspective 
because this is the classic approach to assessing the profit-
ability of societal investments. Using a perspective other 
than the societal increases the risk that maximal health is 
not produced due to inefficiencies in the use of resources 
for health.25 To allow for a more realistic estimate of the 
benefit to society, bevacizumab-based combination therapy 
should be examined from a wider societal perspective as 
well.
This study suggests that societal savings can be made in 
France, Germany, Italy, and Spain in patients who are treated 
with bevacizumab-based therapies when compared with stan-
dard chemotherapy alone. By extending the progression-free 
survival in patients with advanced NSCLC, bevacizumab-
based therapy is favorable from the perspective of society by 
reducing the societal losses associated with this devastating 
disease.
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